| Nov 11 |
NuCana Announces Encouraging Initial Data from Phase 1b/2 Modular Study of NUC-3373 in Combination with Pembrolizumab or Docetaxel
|
| Sep 25 |
NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in the United States
|
| Sep 17 |
NuCana Stock Soars 151% on Upbeat Efficacy Data From Melanoma Study
|
| Sep 16 |
Crude Oil Surges Over 1%; Instil Bio Shares Plunge
|
| Sep 16 |
NuCana's Encouraging Data From Resistant Melanoma Treatment Provides Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
|
| Sep 16 |
NuCana soars on positive data from mid-stage trial for its melanoma treatment
|
| Sep 16 |
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
|
| Sep 14 |
NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024
|
| Aug 21 |
We're A Little Worried About NuCana's (NASDAQ:NCNA) Cash Burn Rate
|
| Aug 15 |
NuCana GAAP EPS of -£0.12
|
